Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 267

1.

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH.

Biol Psychiatry. 2005 Mar 15;57(6):594-608.

PMID:
15780846
[PubMed - indexed for MEDLINE]
2.

The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.

D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH.

Neuropsychopharmacology. 2004 Aug;29(8):1558-72.

PMID:
15173844
[PubMed - indexed for MEDLINE]
Free Article
3.

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS.

Arch Gen Psychiatry. 1994 Mar;51(3):199-214.

PMID:
8122957
[PubMed - indexed for MEDLINE]
4.

Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.

Curran HV, Brignell C, Fletcher S, Middleton P, Henry J.

Psychopharmacology (Berl). 2002 Oct;164(1):61-70. Epub 2002 Jul 23.

PMID:
12373420
[PubMed - indexed for MEDLINE]
5.

Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.

D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E.

Psychopharmacology (Berl). 2008 Jul;198(4):587-603. doi: 10.1007/s00213-007-1042-2. Epub 2008 Jan 29.

PMID:
18228005
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.

Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C, Inghilleri M.

Clin Neuropharmacol. 2009 Jan-Feb;32(1):41-7. doi: 10.1097/WNF.0B013E3181633497.

PMID:
18978501
[PubMed - indexed for MEDLINE]
7.

[Cognition, schizophrenia and the effect of antipsychotics].

Stip E.

Encephale. 2006 May-Jun;32(3 Pt 1):341-50. Review. French.

PMID:
16840928
[PubMed - indexed for MEDLINE]
8.

Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM.

Eur Arch Psychiatry Clin Neurosci. 2009 Aug;259(5):284-92. doi: 10.1007/s00406-009-0868-5. Epub 2009 Feb 17.

PMID:
19224107
[PubMed - indexed for MEDLINE]
9.

Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).

Hunault CC, Mensinga TT, Böcker KB, Schipper CM, Kruidenier M, Leenders ME, de Vries I, Meulenbelt J.

Psychopharmacology (Berl). 2009 May;204(1):85-94. doi: 10.1007/s00213-008-1440-0. Epub 2008 Dec 20.

PMID:
19099294
[PubMed - indexed for MEDLINE]
10.

Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

D'Souza DC, Pittman B, Perry E, Simen A.

Psychopharmacology (Berl). 2009 Mar;202(4):569-78. doi: 10.1007/s00213-008-1333-2. Epub 2008 Sep 21.

PMID:
18807247
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM.

Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77. doi: 10.1016/j.euroneuro.2008.04.008. Epub 2008 Jun 10.

PMID:
18544469
[PubMed - indexed for MEDLINE]
12.

Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol.

Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T.

Psychopharmacology (Berl). 2007 Jun;192(3):325-36. Epub 2007 Feb 28.

PMID:
17333138
[PubMed - indexed for MEDLINE]
13.

Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.

Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, Emrich HM.

Pharmacopsychiatry. 2002 Mar;35(2):57-61.

PMID:
11951146
[PubMed - indexed for MEDLINE]
14.

The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.

Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM.

Psychol Med. 2009 Oct;39(10):1607-16. doi: 10.1017/S0033291709005522. Epub 2009 Apr 1.

PMID:
19335936
[PubMed - indexed for MEDLINE]
15.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
[PubMed - indexed for MEDLINE]
16.

Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.

Schwarcz G, Karajgi B, McCarthy R.

J Clin Psychopharmacol. 2009 Jun;29(3):255-8. doi: 10.1097/JCP.0b013e3181a6bc3b.

PMID:
19440079
[PubMed - indexed for MEDLINE]
17.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
[PubMed - indexed for MEDLINE]
18.

Central nervous system effects of haloperidol on THC in healthy male volunteers.

Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1697-708. doi: 10.1177/0269881109358200. Epub 2010 Feb 8.

PMID:
20142302
[PubMed - indexed for MEDLINE]
19.

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.

Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J.

Schizophr Res. 2007 Dec;97(1-3):109-17. Epub 2007 Sep 19.

PMID:
17884351
[PubMed - indexed for MEDLINE]
20.

Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.

Goodwin RS, Gustafson RA, Barnes A, Nebro W, Moolchan ET, Huestis MA.

Ther Drug Monit. 2006 Aug;28(4):545-51.

PMID:
16885723
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk